effectiveness of oral tirzepatide Safety and efficacy as an add-on to single antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial Oral Tirzepatide Pill: FDA-Approved Options

Although derived from Semaglutide as well, Wegovy is medically recommended for use for weight loss and not to be replaced with Ozempic

This allows enough time between the doses to reduce any impact on absorption

For both injection and tablet formulations, a gradual doseescalation schedule over approximately 16 weeks (injection) or 90 days (tablets) is standard to improve GI tolerability. For prescribers , key considerations include: Confirming that the intended use is FDAapproved (CV risk reduction, chronic weight management, or adult MASH with F2F3 fibrosis) and that BMI and comorbidity criteria are met. Excluding contraindications (MTC/MEN 2, prior anaphylaxis/angioedema to semaglutide) and identifying risk factors such as prior pancreatitis, gallbladder disease, severe GI motility disorders, and advanced diabetic retinopathy

Clinical Research Findings on AOD-9604 In clinical trials involving approximately 900 participants across six human studies, AOD-9604 demonstrated a favorable safety and tolerability profile